Avalo Therapeutics, Inc. (AVTX)

Avalo Therapeutics, Inc. (AVTX) is a healthcare company (biotechnology) based in the United States. The share price is $7.01, down 4.88% on the day, which values the company at $405.34M. Price as of 17 Nov 2026, 17:29 UTC, from Yahoo Finance.

Key facts

Share price
$7.01−4.88% today
Market value
$405.34M
Funk Score
19/100
Against its own history
About its usual priceusual price $6.68
200-week average
$90.9392% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Avalo Therapeutics, Inc. in more detail

AVTX trades at -2.7× next year's expected earnings, 6870.2× sales. Measured against its own history, the price is 5% above what its usual multiples would imply ($6.68) — about its usual price. It sits 92% below its 200-week average of $90.93.

Over the last five fiscal years Avalo Therapeutics, Inc. has compounded revenue -61.2% a year. Its Funk Score is 19 out of 100 (financial strength 4.1, profitability 0.3, growth 0.7, value 2.5, each out of 10).

In its favour: More cash than debt. Worth checking: Altman Z in the distress zone; Weak Piotroski score.

3 of the superinvestors tracked here hold AVTX, including Andrew Spokes (0.3% of the portfolio), Peter Kolchinsky (0.2% of the portfolio), Julian and Felix Baker (0.1% of the portfolio).

Superinvestors holding AVTX

3 of the investors tracked here report a position in their latest 13F filing.

Avalo Therapeutics, Inc. (AVTX): questions and answers

What is Avalo Therapeutics, Inc.'s market cap?

Avalo Therapeutics, Inc. is valued at $405.34M at a share price of $7.01.

Is AVTX overvalued or undervalued?

Against its own history, AVTX is about its usual price: the price is 5% above the $6.68 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is AVTX above its 200-week moving average?

No. AVTX is 92.3% below its 200-week average of $90.93. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Avalo Therapeutics, Inc. growing?

Over the last five fiscal years Avalo Therapeutics, Inc.'s revenue grew -61.2% a year.

Does AVTX pay a dividend?

Avalo Therapeutics, Inc. does not currently pay a regular dividend.

Which famous investors own AVTX?

In their latest quarterly filings, Andrew Spokes (0.3% of the portfolio), Peter Kolchinsky (0.2% of the portfolio), Julian and Felix Baker (0.1% of the portfolio) hold AVTX. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Avalo Therapeutics, Inc. (AVTX) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/AVTX

Underlying data: Yahoo Finance; company filings with the SEC.